(Q37988792)

26 August 2017

title

Drug development and clinical trials--the path to an approved cancer drug (English)

1 reference

26 August 2017

Eric H Rubin

1

1 reference

26 August 2017

D Gary Gilliland

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

28 February 2012

1 reference

Nature Reviews Clinical Oncology

26 August 2017

published in

1 reference

26 August 2017

volume

9

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

215-222

1 reference

Trends in risks associated with new drug development: success rates for investigational drugs

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

High drug attrition rates--where are we going wrong?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Volumes to learn: advancing therapeutics with innovative computed tomography image data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Believe it or not: how much can we rely on published data on potential drug targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Trial watch: Phase II failures: 2008-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Common gene rearrangements in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Utilizing RNA interference to enhance cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Making the best of PARP inhibitors in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Trends in the use and role of biomarkers in phase I oncology trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Early accelerated approval for highly targeted cancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Multiplicity adjustment big and small in clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Implementing personalized medicine in a cancer center

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

On the eve of personalized medicine in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Phase II trials powered to detect tumor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Overall survival as the outcome for randomized clinical trials with effective subsequent therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Detecting an overall survival benefit that is derived from progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Progression-free survival is a surrogate for survival in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

The use of volumetric CT as an imaging biomarker in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Evaluating the efficiency of targeted designs for randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.22

Outcome--adaptive randomization: is it useful?

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22371130

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2012.22

1 reference

26 August 2017

1 reference